Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study

Pemetrexed Plus Lenalidomide for Relapsed/Refractory Primary Central Nervous System Lymphoma: A Prospective Single-Arm Phase II Study

The prognosis of relapsed/refractory (R/R) primary central nervous system lymphoma (PCNSL) is dismal, and there are limited treatment options for these patients. This was a prospective single-arm phase II study of combined pemetrexed and lenalidomide for salvage treatment of R/R PCNSL. Patients with...

Full description

Bibliographic Details
Main Authors: Jingjing Ma, Zhiguang Lin, Tianling Ding, Qing Li, Mengxue Zhang, Hui Kang, Patrick B. Johnston, Yan Ma, Bobin Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
primary central nervous system lymphoma
relapsed/refractory
pemetrexed
lenalidomide
efficacy and safety
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.938421/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.938421/full

Similar Items